HOPE ON THE HORIZON APRIL 11, 2019
Hyperbaric Oxygen Therapy for Alzheimer’s
I am seeing an upturn in reports about a variety of less invasive or non-invasive treatments for Alzheimer’s disease. The lack of success of drug trials may be partly responsible. Here is a potential one that uses the therapy used to treat divers with decompression sickness (the bends). Investigators in a resent study used hyperbaric oxygen therapy for Alzheimer’s to treat a women whose pathology was progressing rapidly.
What Is Hyperbaric Oxygen Therapy for Alzheimer’s?
Hyperbaric oxygen therapy (HBOT) introduces pure oxygen into the lungs under pressure. This increases the amount of oxygen available to damaged tissue and promotes healing.
A hyperbaric chamber in use
Although hyperbaric oxygen therapy is best recognized as a treatment for a hazard of scuba diving, it is used to treat a host of other conditions and injuries. Included in this list are non-healing wounds and burns, skin and bone infection, and crushing injuries and gangrene.
The current paper, Hyperbaric oxygen therapy for Alzheimer’s dementia with positron emission tomography imaging: A case report1, documents evidence for improvement in brain metabolism. The study also found a reversal of the normal symptomatic progression of the disease resulting from the treatment. The authors conclude that these results, “suggests an effect on global pathology in AD.”
The study is a collusion between two researchers at different medical schools. Dr. Paul Harch is the director of Medicine at Louisiana State University (LSU) Health New Orleans School of Medicine. Dr. Edward Fogarty is chairman of Radiology at the University of North Dakota (UND) School of Medicine.
A spokesman from Mayo Clinic rightly points out that more trials are necessary before anyone gets too excited about hyperbaric oxygen therapy for Alzheimer’s disease. The current study, published in January in the peer-reviewed journal Medical Gas Research, used HBOT to treat one subject with Alzheimer’s disease.
Mayo’s concern is understandable. This case report must be considered preliminary and non-conclusive as it only involved one subject, a 58-year-old woman. She had been diagnosed with Alzheimer’s disease with symptoms that were progressing rapidly prior to the beginning of the study. On mayoclinic.org they point out that, “The evidence is insufficient to support claims that hyperbaric oxygen therapy can effectively treat the following conditions,” and include:
- AIDS/HIV
- Alzheimer’s disease
- Arthritis
- Asthma
- Autism
- Brain injury
- Cancer
- Cerebral palsy
- Chronic fatigue syndrome
- Cirrhosis
- Spinal cord injury
- Depression
- Fibromyalgia
- Heart disease
- Multiple sclerosis
- Parkinson’s disease
- Sports injury
- Stroke
More Research is Needed
Mayo Clinic is probably just exercising a healthy scientific reserve until more experimental evidence is available. Russia and China are both reporting success treating as many as 100 different conditions with HBOT. But Russia and China have fewer restrictions on research than does the United State. On the other hand, there are researchers in this country who are expanding the horizons for HBOT. For example, a 2013 study* published in the peer reviewed journal PLOS ONE reported significant anti-cancer effect when HBOT was combined with a ketogenic diet.
So there is some evidence that this therapy might in the future be used to treat a broad range of conditions and diseases.
SCIENCE AND MEDICINE
M3 Biotechnology Announces Name Change to Athira Pharma, Inc.
Press Release
The company plans to launch a phase 2 proof-of-concept study before the end of 2019 to examine the drug’s long-term safety and other exploratory endpoints. Meanwhile, preliminary results from the ongoing, placebo-controlled phase 1 study will be presented at a scientific conference midyear, Athira said.
According to the press release, “Preclinical studies of NDX-1017 have demonstrated the ability of the compound to promote neuro-regeneration and improve cognitive function. A Phase 2 proof-of-concept study is planned to start in 2019 to evaluate the effects of NDX-1017 for long-term safety and exploratory endpoints.”
Doctors plan to test a gene therapy that could prevent Alzheimer’s disease
MIT Technology Review
Scientists know that a type of younger onset Alzheimer’s disease, called familial Alzheimer’s, results from inherited mutations in one of three genes. Though this familial type accounts for as little as 2% to 3% of all cases of Alzheimer’s disease, some scientists believe that studying it may lead to a better understanding of the genetic link to the disease in general.
Another gene called APOE is known to have a connection to later-onset Alzheimer’s disease. There are three types of this gene; APOE2, E3, and E4, and they influence risk in different ways. The rarest form is E2, and is thought to reduce the risk for Alzheimer’s by as much as 40%. E3 seems not to influence risk at all. The APOE4 version can increase risk by up to sixteen times. It also lowers the age of the disease’s onset. It is present in 10-15% of the population.
So pervasive is the connection between the presence of this gene and the disease that the National Institute of Health recommends testing for it only in the case of clinical trials. Knowing that one has this gene can be very upsetting, as genetic makeup can’t be changed.
At least it can’t be changed at this time. A team of researchers led by Ronald Crystal at Weill Cornell Medicine in New York is hoping to change that. The team plans to start a gene therapy trial in May. The subjects will be people who have tested positive for the APOE4 gene, and are at a high risk for developing the disease. The treatment will involve a high dose of the protective APOE2 gene.
This is very experimental, but certainly worth watching.
BE A PART OF THE SOLUTION
Alzheimer Prevention Trials Webstudy
The Alzheimer Prevention Trials (APT) Webstudy is an online registry designed to accelerate enrollment for Alzheimer’s disease clinical trials by identifying and tracking individuals who may be at higher risk for developing Alzheimer’s dementia.
Study Start Date: December 20, 2017
Study End Date: April 30, 2022
If you are at least 50 years of age and interested in Alzheimer’s research, please join
.
After signing up, participants will go online to fill out a brief assessment of their cognitive abilities and complete a 20-minute test to assess their memory and thinking skills. The test will be repeated every 3 months, and participants will have access to their scores.
.
Why Join apt webstudy
- Access to secure, personalized, web-based tools to assess and track your cognitive performance
- Opportunity to participate in comprehensive evaluations at one of our nationwide clinical sites
- Opportunity to participate in clinical trials to prevent Alzheimer’s disease
This project is funded in part by a grant from the National Institute on Aging, National Institute of Health
Ongoing NDX-1017 Clinical Trials (see Athira Pharma above)
To inquire about participation in the current Phase 1 clinical trials of NDX-1017, please contact 1-800-839-2095 or visit www.ndx-1017.com. In France, contact our clinical partner, Biotrial, at 0 800 503 460. Further details on the study can be found on clinicaltrials.gov.
PREVENT AND PROTECT
How consumption of coconut oil can help prevent Alzheimer’s disease
Business Standard
A little late to the party, Business Standard reported last week on the possible benefits of virgin coconut oil in Alzheimer’s prevention.
Coconut oil is a topic we have been pursuing for years. Read more»
Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation
Frontiers in Neuroscience
More exciting news, at least for us coffee drinkers. Researchers have reported a connection between coffee consumption and a reduced risk of Alzheimer’s and Parkinson’s, but the mechanism at work was not understood. A group of researchers in Toronto hypothesized that the compounds in brewed coffee offer protection against the accumulation of proteins in the brain. That includes the plaques and tangles that are hallmarks of Alzheimer’s disease as well as α-synuclein, the protein associated with Parkinson’s disease.
However, it may not be the caffeine. The researchers looked at 6 compounds found in coffee. These are caffeine, chlorogenic acid, quinic acid, caffeic acid, quercetin, and phenylindane. Some bad news for cola drinkers—caffeine by itself offered no protection against amyloid plaques or fibrillary tangles, or against α-synuclein. Phenylindane demonstrated the highest degree of protection, but the authors to posit a synergistic effect among several or all of the compounds.
Golden MilkJuly 31, 2019 - 4:31 PM
How is Lewy body dementia different from Alzheimer’s?July 15, 2019 - 4:14 PM
Dementia or Vitamin B12 deficiency?July 11, 2019 - 11:29 AM
What is Dementia?July 3, 2019 - 2:46 PM
THE IMPORTANCE OF AN ACCURATE ALZHEIMER’S DIAGNOSISJune 21, 2019 - 10:25 AM
Fall Related Deaths are IncreasingJune 7, 2019 - 11:34 AM
Organizations & Affiliations
Purple Angel Ambassador
Dementia Friendly America
Leave a Reply
Want to join the discussion?Feel free to contribute!